Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 11, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Uterine leiomyosarcoma: an updated series.

Jose Alejandro Rauh-Hain1, Titilope Oduyebo, Elisabeth J Diver

  • 1Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|May 30, 2013
PubMed
Summary

Tumor size and mitotic count are key factors influencing survival in uterine leiomyosarcoma (ULMS). Early-stage ULMS survival is linked to tumor size and mitosis, while late-stage survival primarily depends on mitotic count.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.

JCO precision oncology·2026
Same author

A pooled analysis of phase 2 clinical trials in advanced chordoma.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Clinicopathologic Study of 39 Mismatch Repair-deficient Sarcomas Demonstrates Recurrent Histologic Patterns and Supports Universal Screening of Pleomorphic Rhabdomyosarcoma, Uterine Leiomyosarcoma, and Undifferentiated and Unclassified Sarcomas.

The American journal of surgical pathology·2026
Same author

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Nature medicine·2026
Same author

Severe Early-Onset Fetal Growth Restriction: The Yield of Antenatal and Postnatal Genetic Testing.

Prenatal diagnosis·2026
Same author

Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Area of Science:

  • Gynecologic Oncology
  • Surgical Pathology
  • Cancer Research

Background:

  • Uterine leiomyosarcoma (ULMS) is a rare and aggressive malignancy.
  • Understanding prognostic factors is crucial for patient management and treatment strategies.

Purpose of the Study:

  • To analyze and compare clinicopathologic characteristics, treatment, and survival outcomes in patients with ULMS.
  • To identify independent predictors of overall survival (OS) in early and late-stage ULMS.

Main Methods:

  • Retrospective analysis of 167 ULMS patients treated between 2000 and 2010 across three academic centers.
  • Diagnosis confirmed by gynecologic pathologists; survival data analyzed using Kaplan-Meier, log-rank test, and Cox regression.

Main Results:

Related Experiment Videos

Last Updated: May 11, 2026

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

  • Tumor size (≥11 cm) and high mitotic count (≥25/10 HPF) were independent predictors of OS in early-stage ULMS.
  • High mitotic count (≥25/10 HPF) was the sole independent predictor of OS in late-stage ULMS.
  • Significant differences in median OS were observed across stages I-IV (20-75 months).

Conclusions:

  • Tumor size and mitotic count are critical prognostic indicators for early-stage ULMS.
  • Mitotic count is the primary independent predictor of survival in advanced-stage ULMS.
  • These findings aid in risk stratification and personalized treatment approaches for ULMS.